Company intelligence / Profile preview

Zhejiang Echon Biopharm

Zhejiang Sheng, Chinasciencedirect.com ↗

Ownership: Private
Development stage: Other

Overview

Zhejiang Echon Biopharm Limited, founded in China in 2017, develops recombinant polypeptide drugs with a primary focus on infectious, respiratory, and oral/mucosal diseases. Its lead asset GB001 recombinant peptide spray targets mild recurrent aphthous ulcer and has reached Phase IIa clinical trials as of early/mid–2025. The company appears to have at least two pipeline programs but detailed results are not publicly available. No major licensing deals or partnerships are disclosed.

Therapeutic areas: OtherGastroenterologyPulmonologyInfectious Diseases
Modalities: Recombinant polypeptideRecombinant peptidePeptide (as a general class)
Industry: Biotech

Drug pipeline

1 asset

GB001 (Zhejiang Echon Biopharm)

Unknown

Beyond the preview

Go deeper on Zhejiang Echon Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Echon Biopharm.

Explore the full profile